A detailed history of Jfs Wealth Advisors, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Jfs Wealth Advisors, LLC holds 8 shares of RCUS stock, worth $121. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Previous 7 14.29%
Holding current value
$121
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 30, 2024

BUY
$14.83 - $20.18 $14 - $20
1 Added 14.29%
8 $0
Q4 2023

Feb 07, 2024

SELL
$13.43 - $19.63 $53 - $78
-4 Reduced 36.36%
7 $0
Q3 2023

Nov 02, 2023

BUY
$17.62 - $23.54 $35 - $47
2 Added 22.22%
11 $0
Q2 2023

Aug 07, 2023

BUY
$16.97 - $22.03 $118 - $154
7 Added 350.0%
9 $0
Q1 2023

Apr 19, 2023

SELL
$15.96 - $23.15 $223 - $324
-14 Reduced 87.5%
2 $0
Q4 2022

Feb 13, 2023

BUY
$19.7 - $35.71 $118 - $214
6 Added 60.0%
16 $0
Q3 2022

Oct 21, 2022

BUY
$23.23 - $30.07 $185 - $240
8 Added 400.0%
10 $0
Q2 2022

Aug 02, 2022

SELL
$17.23 - $37.73 $34 - $75
-2 Reduced 50.0%
2 $0
Q1 2022

May 02, 2022

BUY
$28.92 - $41.83 $57 - $83
2 Added 100.0%
4 $0
Q4 2021

Feb 03, 2022

BUY
$31.38 - $48.47 $62 - $96
2 New
2 $0

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.1B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Jfs Wealth Advisors, LLC Portfolio

Follow Jfs Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.